Single Ascending Oral Doses of SY-009 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions
Diabetes
Interventions
DRUG

SY-009

The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Trial Locations (1)

100000

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Suzhou Yabao Pharmaceutical R&D Co., Ltd.

INDUSTRY

NCT04119947 - Single Ascending Oral Doses of SY-009 in Healthy Subjects | Biotech Hunter | Biotech Hunter